The platform features an enhanced user experience and end-to-end breast workflow with automated H&E analysis and “zero-click” IHC quantification, supporting more efficient and accurate scoring of HER2, ER, PR and Ki67
BOSTON–(BUSINESS WIRE)–Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced the launch of Ibex 4, its next-generation platform. Built on Ibex’s clinically validated algorithms1-10 and developed in close collaboration with the world’s leading pathology labs, Ibex 4 is designed to transform the diagnostic journey, delivering unprecedented value to pathologists, laboratories, and patients.
As pathology departments worldwide face rising case volumes and increasing diagnostic complexity, Ibex 4 provides a future-ready solution that alleviates these pressures. “Ibex 4 was designed to help pathologists ‘see more and click less,’ focusing their expertise where it matters most,” said Chaim Linhart, CTO at Ibex Medical Analytics. “One example is Ibex Breast’s “zero-click” IHC quantification and visualization tools, which are particularly useful in identifying a few stained cells and very low levels of HER2 expression, as well as quickly calculating the Ki67 proliferation index. Ibex is empowering pathologists to overcome interobserver variability and ensure every patient receives the most precise diagnostic results and insights.”
A Complete Breast Solution: From H&E to IHC
Central to the Ibex 4 release is the expansion of the Ibex Breast offering. The platform now supports an end-to-end diagnostic workflow for biopsies and excisions. Ibex Lymph Node, first available for research use, will be available soon.
- H&E Optimization: Ibex Breast detects >50 tissue morphologies, supporting more accurate and efficient diagnosis. By pre-screening for invasive cancer and DCIS, the platform can pre-order IHCs to optimize lab workflows.
- “Zero-Click” IHC Scoring: The platform automatically identifies invasive cancer areas and quantifies HER2, ER, PR, and Ki67-stained cells. Pathologists supported by Ibex Breast HER2 showed improved HER2 scoring accuracy and consistency, as demonstrated by an early evidence program across 14 international reference laboratories and cancer centers.8 An additional multi-center study will be presented at USCAP 2026, demonstrating that Ibex Breast ER, PR, and Ki67 bolster scoring precision and interobserver concordance.10
- Precision Medicine Support: Ibex Breast enhances support for borderline and low HER2 expression identification. A new and specialized feature assists pathologists in the detection and interpretation of cases with HER2 ultralow expression by enhancing visualization of cell staining, a time-consuming task known for high subjectivity. As demonstrated in a recent study presented at San Antonio Breast Cancer Symposium 2025, Ibex AI helped identify 57% more patients potentially eligible for targeted therapy by correcting over half of false HER2 0 (null) classifications to HER2 Ultralow or 1+.8 Ibex AI also aided in reducing equivocal scoring and reliance on additional testing (FISH).8
Streamlined Workflow & Increased Efficiency
Ibex 4 introduces a sophisticated user interface, customized reporting, and advanced workflow integrations that increase efficiency:
- Prioritized Insights & Visualization: High-likelihood findings are automatically surfaced to the top of the worklist and coupled with Ibex’s trademark heatmaps and a new points of interest (POI) gallery, rapidly guiding pathologists to critical tissue areas for faster, more accurate confirmation.
- Proven Prostate & Gastric Support: Ibex 4 continues to power market-leading solutions for prostate and gastric cancer, ensuring efficiency across the lab’s highest-volume case types. New Ibex Prostate indications include support for cribriform patterns, Transurethral Resection of the Prostate (TURP), and Lumea BxChip.
- Customized Reporting: AI-powered automation enables efficient case reporting via LIS integration, saving pathologists’ time and enabling focus on diagnosis while reducing administrative tasks.
- Partnerships & Integrations: Recognizing the importance of seamless lab workflows, Ibex continues to partner with industry leaders on LIS and IMS integrations that make it easier than ever for pathologists to incorporate the AI technology into daily practice.
Ibex Medical Analytics remains at the forefront of AI-driven pathology, continuously evolving to meet the needs of pathologists and improve patient outcomes. The company recently announced expansion of its biopharma business, extending the AI-powered product offering into biomarker development. Ibex is proud to share these new advancements and looks forward to further innovation.
Information on Ibex 4 and live demos will be available at the 115th USCAP Annual Meeting in San Antonio, TX, USA, between March 21-26 (Ibex Medical Analytics – booth number 231).
About Ibex Medical Analytics
Ibex is the global leader in clinical-grade AI for pathology, with hundreds of clinically deployed solutions and partnerships spanning life-science companies, reference laboratories, and digital pathology vendors. Ibex’s platform supports biomarker discovery, clinical trial efficiency, and CDx-ready evidence generation, backed by an ISO 13485-compliant QMS.
Ibex Breast includes the Ibex platform solutions for Breast H&E (biopsies and excisions) and Breast IHC (HER2, ER, PR, Ki67). The Ibex platform includes solutions that are CE-IVD certified and registered with MHRA in the UK, TGA in Australia, ANVISA in Brazil, AMAR in Israel & Swissmedic in Switzerland. It includes a solution that is FDA cleared and others that are Research Use Only (RUO) in the United States.
For additional company information, please visit and follow us on LinkedIn and X.
- Pantanowitz et al. Lancet Digital Health (2020) 2(8): e407-e416.
- Santa-Rosario et al. Journal of Pathology Informatics (2024), 15:100378.
- Lami et al. Pathology (2024), 56; 5:633-642
- Borkowski et al. Quest Diagnostics, Proscia, Ibex 2024.
- Tahir et al. Clin Breast Cancer. 2025
- Sandbank et al. NPJ Breast Cancer 2022
- Krishnamurthy et al. JCO Precis Oncol 8, e2400353(2024).
- Vecsler et al. Presented at SABCS 2025
- Rodriguez-Justo et al. Virchows Arch. 2023. 483 (Suppl 1): 1.
- Vincent-Salomon et al. To be presented at USCAP 2026.
Contacts
Tamar Brosh
Head of Marketing, Ibex Medical Analytics
tamar.brosh@ibex-ai.com
